Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.53 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.53 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.53 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | TUBB4A | P04350 | 4/20 | 0.52 |
| ▸ | TUBB | P07437 | 4/20 | 0.52 |
| ▸ | TUBA3C | P0DPH7 | 4/20 | 0.52 |
| ▸ | TUBA1B | P68363 | 4/20 | 0.52 |
| ▸ | TUBA4A | P68366 | 4/20 | 0.52 |
| ▸ | TUBB4B | P68371 | 4/20 | 0.52 |
| ▸ | TUBB3 | Q13509 | 4/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL96635 | 0.98 | ALDH1A1 (0.59) | ALDH1A1TSHRCYP1A1CYP1A2CYP1B1 | |
| SCHEMBL16619850 | 0.98 | ALDH1A1 (0.59) | ALDH1A1TSHRCYP1A1CYP1A2CYP1B1 | |
| Alcohol SCHEMBL28096074 | 0.88 | ALDH1A1 (0.51) | ALDH1A1TSHRCYP1A1CYP1A2CYP1B1 | |
| SCHEMBL28788062 | 0.88 | ALDH1A1 (0.50) | ALDH1A1TSHRCYP1A1CYP1A2CYP1B1 | |
| Phosphoric Acid SCHEMBL26634475 | 0.88 | ALDH1A1 (0.51) | ALDH1A1TSHRCYP1A1CYP1A2CYP1B1 | |
| SCHEMBL17655658 | 0.87 | ALDH1A1 (0.53) | ALDH1A1TSHRCYP1A1CYP1A2CYP1B1 | |
| SCHEMBL30634410 | 0.86 | ALDH1A1 (0.54) | ALDH1A1TSHRCYP1A1CYP1A2CYP1B1 | |
| SCHEMBL9135687 | 0.86 | ALDH1A1 (0.48) | ALDH1A1TSHRCYP1A1CYP1A2CYP1B1 | |
| SCHEMBL28944930 | 0.85 | ALDH1A1 (0.52) | ALDH1A1TSHRCYP1A1CYP1A2CYP1B1 | |
| SCHEMBL5045913 | 0.85 | ALDH1A1 (0.52) | ALDH1A1TSHRCYP1A1CYP1A2CYP1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4514342-A1 | POLYMORPHS OF [2-(1-INDOL-3-YL)-1H-IMIDAZOL-4-YL](3,4,5- TRIMETHOXY)METHANONE AND ITS SALTS | Veru Inc. (US) | 2025-03-05 | — | — | EP | claimed |
| WO-2023212252-A1 | POLYMORPHS OF [2-(1H-INDOL-3-YL)-1H-IMIDAZOL-4-YL](3,4,5- TRIMETHOXY)METHANONE AND ITS SALTS | VERU INC. (US) | 2023-11-02 | — | — | WO | claimed |
| EP-4514342-A1 | POLYMORPHS OF [2-(1-INDOL-3-YL)-1H-IMIDAZOL-4-YL](3,4,5- TRIMETHOXY)METHANONE AND ITS SALTS | Veru Inc. (US) | 2025-03-05 | — | — | EP | disclosed |
| EP-4504183-A1 | METHODS OF TREATING INFLUENZA AND POXVIRUS VIRAL INFECTIONS | Veru Inc. (US) | 2025-02-12 | — | — | EP | disclosed |
| WO-2023212252-A1 | POLYMORPHS OF [2-(1H-INDOL-3-YL)-1H-IMIDAZOL-4-YL](3,4,5- TRIMETHOXY)METHANONE AND ITS SALTS | VERU INC. (US) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023196632-A1 | METHODS OF TREATING INFLUENZA AND POXVIRUS VIRAL INFECTIONS | VERU INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| CN-115379835-A | Methods of treating coronavirus | 维鲁公司 | 2022-11-22 | — | — | CN | disclosed |
| US-11084811-B2 | Compounds for treatment of cancer | Oncternal Therapeutics, Inc. (US) | 2021-08-10 | — | — | US | disclosed |
| CN-112512522-A | Compounds for the treatment of triple negative breast and ovarian cancer | 田纳西大学研究基金会 | 2021-03-16 | — | — | CN | disclosed |
| CN-112437664-A | Compounds for the treatment of pancreatic cancer | 田纳西大学研究基金会 | 2021-03-02 | — | — | CN | disclosed |
| CN-103442566-B | The compound of Therapeutic cancer | GTX, INC. (US) | 2015-12-09 | — | — | CN | disclosed |
| CN-102883607-B | Compounds for the treatment of cancer | GTX INC | 2015-07-22 | — | — | CN | disclosed |
| CN-104592205-A | COMPOUNDS FOR TREATMENT OF CANCER | GTX INC | 2015-05-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11084811-B2 | Compounds for treatment of cancer | KLK3, BRDT, ACP3 | GAA 1027/4885HTR1A 4779/4885HTR2C 4556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.